Virco News

July 5, 2005. As of July 5 2005, Tipranavir (TPV, Aptivus®) will be added to the drug menu of the virco®TYPE HIV-1 report. Aptivus® is the newest FDA approved protease inhibitor (June 22, 2005) aimed at blocking HIV replication, and should be co-administered with 200 mg of ritonavir (Norvir®)....

June 15, 2005. Virco is pleased to announce from today onwards the virco®TYPE HIV-1 report with integrated Clinical Cut-Off values will be available. Compared to Biological Cutoffs, Virco®TYPE HIV-1 with Clinical Cut-Offs provides greater accuracy in predicting virological response (Winters et al., 12th Conference on Retroviruses and Opportunistic Infections,...

May 15, 2005. With the release of vircoNET™ V 1.9 and implementation of the Hermes Reporting and Apollo IM systems for Virco, real time reporting for virco®TYPE HIV-1 reports has become standard practice. As from now, half of the virco®TYPE HIV-1 reports are available in less than 10 minutes,...

Athens, March 30-April 1. By common consent, one of the highlights of the recent European Resistance Workshop held in Athens was the session on Clinical Cut-Offs chaired by Francoise Brun-Vezinet and Rob Schuurman, in which presentations were made by both ViroLogic and Virco. Michael Bates, Vice President Clinical Research...

The first from Alex Rinehart, titled: "Evolution in the Diversity of HIV-1 Resistance Mutation Patterns in >128,000 Clinical Samples Received for Resistance Analysis from 1998 to 2004." Abstract #: M-221 Session: 117. HIV Drug Resistance: Selection, Evolution, and Persistence Poster Board #: 684 Day/Date: Wednesday, February 23, 2005 Session...

The Virco abstract by Dr. Lee Bacheler, "Evaluation of Phenotypic Clinical Cutoffs for Virco®TYPE HIV-1derived by Meta Analyses of Clinical Trial and Cohort Data" has been accepted for an oral presentation at the 3'rd European HIV Drug Resistance Workshop, Athens Greece, in the session "Clinical implications", on Friday, April...

In the November 2004 issue of the Journal of AIDS, investigators of the PhenGen trial reported more good news about virco®TYPE HIV-1. When compared to Antivirogram®, virco®TYPE HIV-1 (at the time of the study still called VirtualPhenotype™) was just as effective to help doctors select optimal combinations of drugs...

Washington, D.C., October 31, 2004 - Investigators from Virco today presented data that establishes a comprehensive set of clinical cutoffs - a newly established threshold for optimal selection and evaluation of antiretroviral regimens - for the virco ® TYPE HIV-1 resistance test. These reference values are derived from the...

Virco is pleased to introduce its new HIV-1 resistance testing service vircoTYPE HIV-1 , available as from July 12, 2004. Phasing in during the month of July, the new virco ® TYPE HIV-1 service wiil gradually replace the existing Virtual Phenotype ™ service. Virco ® TYPE HIV-1 is designed...

Virco has recently entered into an agreement with the "Centro de Genomas" from Sao Paolo, Brazil. Under the terms of the agreement Centro de Genomas will provide Virco's products, Antivirogram® and Virtual Phenotype™ to the private and public sectors throughout the country. According to professor Ricardo Sobhie Diaz, a...